Resource Library

BLUPrInt PrEP Program Builder

The BLUPrInt PrEP Program Builder breaks down the process of making PrEP – whether oral or injectable – available in your setting into six manageable and coherent program components. Each program component includes a Step-by-Step Guide that presents key decision points and health equity considerations that are crucial to PrEP program development, a templated Standard…

Demand Creation/Marketing, Service Delivery, Supply Chain Management

Site/Facility Readiness Assessment Tool to Support Lenacapavir for HIV Prevention Introduction

This tool, developed by Wits RHI and CHAI with support from Unitaid, is intended to provide insight into the current state of PrEP services and to identify critical barriers and facilitators to PrEP implementation with a focus on preparing for Lenacapavir (LEN) introduction according to national requirements. Findings from readiness assessment visits using this tool…

Service Delivery

Consolidated Guidelines for the Prevention and Treatment of HIV and AIDS in Uganda, 2022

These guidelines, produced in 2022 by the Uganda Ministry of Health, provide guidance on the diagnosis of HIV, the care of people living with HIV, and the use of antiretroviral drugs for treating and preventing HIV infection, including injectable cabotegravir and the dapivirine vaginal ring.

Normative Guidance/Policies

Malawi Service Delivery Guidelines and Standard Operating Procedures for the Provision of HIV Pre-Exposure Prophylaxis using Oral or Long-acting Injectable Options (2024)

The document, produced by the Malawi Ministry of Health, is a guideline to support funders, implementing partners, district health team leads and service providers in implementing Oral and Long-Acting Injectable PrEP in Malawi.

Normative Guidance/Policies

Innovative HIV Prevention and Treatment Keynote and Panel Discussion

Can a Twice-Yearly PrEP Injection Curb the HIV Pandemic? Join the O’Neill Institute for an in-depth discussion on Lenacapavir, a groundbreaking long-acting injectable PrEP formulation administered just twice a year. This session will examine its potential to transform HIV prevention on a global scale, looking at the latest clinical evidence, regulatory pathways, and the access…

Preferences for Long-acting Injectable HIV Pre-exposure Prophylaxis Service Delivery among Male and Female Sex Workers in Uganda: A discrete choice experiment

This article from PLOS Global Public Health explores service delivery preferences for injectable cabotegravir among heterosexual male sex workers and female sex workers in Uganda.

Research, Service Delivery

Lenacapavir Provider Tools and Job Aids

These editable tools, developed by Wits RHI, can be used to support providers delivering lenacapavir (LEN) for PrEP. The downloadable zip file includes: LEN Factsheet for Clients LEN Counselling Job Aid for Clinicians LEN Counselling Job Aid for Counsellors LEN Initiation Algorithm LEN Injection Procedure Chart HIV Prevention Product Comparison Table LEN Stopping and Switching…

Service Delivery

The New Frontier in HIV Pre-exposure Prophylaxis: Lenacapavir Update

In the ongoing search for new methods to address the HIV epidemic, the development of lenacapavir for HIV prevention is a major step forward. Findings from research studies has shown that twice-yearly injection of long-acting lenacapavir provides protection against HIV infection. This discovery offers great promise in advancing our progress towards ending AIDS as a…

Research

Prevention with PURPOSE

This presentation, delivered by Dr Linda-Gail Bekker at IAS 2025, provides an overview of PURPOSE 1 and 2 lenacapavir clinical trial results as well as special considerations for administration to different populations and drug-drug interactions.

Research

Dynamic Choice HIV Prevention with Long-acting Injectable Cabotegravir Pre-exposure Prophylaxis in East, Central, Southern, and West Africa: A cost-effectiveness modelling analysis

In randomised controlled trials in Kenya and Uganda, a dynamic choice HIV prevention intervention that offered structured choice of biomedical prevention product and opportunity to change products over time substantially improved prevention coverage; incident HIV infections were eliminated when long-acting cabotegravir was included as an option. This article from The Lancet HIV aims to assess…

Financing & Costing, Research, Service Delivery